Home/Sutro Biopharma/David Pauling
DP

David Pauling

Chief Administrative Officer and General Counsel

Sutro Biopharma

Therapeutic Areas

Sutro Biopharma Pipeline

DrugIndicationPhase
Luveltamab tazevibulin (STRO-002)Folate receptor-alpha (FolRα) expressing ovarian cancerPhase 2/3
STRO-003ROR1-expressing solid tumorsPreclinical
Next-generation ADCsUndisclosed cancersDiscovery/Preclinical
Cytokine-based Immuno-oncologyUndisclosed cancersResearch